Two new breast cancer drugs now available on NHS England after U-turn (2024)

FAQs

Two new breast cancer drugs now available on NHS England after U-turn? ›

The two new drugs, Alpelisib (also known as Piqray) and Trodelvy (also called Sacituzumab Govitecan) are finally now available on NHS England, after previously being rejected earlier on this year.

A targeted drug for advanced breast cancers

Talazoparib is recommended for advanced breast cancers with cells that don't have receptors for a protein called HER2, which can be effectively targeted by other drugs.

New Treatments for Breast Cancer: Abraxane, Herceptin, Aromatase Inhibitors, and Oncotype Assays.

Talazoparib (Talzenna)

NICE approved the drug talazoparib for use on the NHS in England in January. Talazoparib is a drug for certain people with locally advanced or secondary breast cancer who've inherited an altered BRCA gene.

A new class of drugs known as CDK4/6 inhibitors are approved. CDK4/6 inhibitors have shown promise in the treatment of advanced ER-positive breast cancer.

The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi, who presented the findings at this year's American Society of Clinical Oncology (ASCO) meeting.

Thousands more women with breast cancer could benefit from a blockbuster immunotherapy drug than previously thought, research suggests. Pembrolizumab, sold under the brand name Keytruda, targets and blocks a specific protein on the surface of certain immune cells that then seek out and destroy the cancerous cells.

You take tamoxifen daily at the same time every day. To treat early breast cancer, most people take tamoxifen for 5 years. In some situations, you might take it longer. This might be up to 10 years.

Leaders at City of Hope, one of the largest cancer research and treatment organizations in the United States, forecast that in 2024 more people will benefit from cancer breakthroughs, including research that unlocks the biology behind cancer disparities, wider access to CAR T cell therapy and rapid whole genome ...

Currently, survival rates exceed 90 percent in HER2-positive breast cancer that is diagnosed early and treated with chemotherapy and dual antibody therapy.

What is the 7 minute cancer injection in England? ›

"Drug treatment times for some NHS cancer patients will be slashed by up to three quarters, thanks to an anti-cancer injection that takes as little as seven minutes to administer," NHS said in an official statement. With this, the patients will be administered atezolizumab under the skin injection.

In a 2022 study, researchers found that Trodelvy, an ADC that targets a surface protein known as TROP2, seemed to be more effective than standard chemotherapy for people with metastatic triple-negative breast cancer, a particularly hard-to-treat disease.

"Blinatumomab is a gentler, kinder treatment." Another targeted immunotherapy drug, chimeric antigen receptor T-cell therapy (CAR-T), has also recently become available.

Many women with metastatic breast cancer will live only a handful of years, says Hendershott. But about one-third will live at least five years after their diagnosis. And “there are people who have been living with stage IV breast cancer for more than 15 years,” she says.

Shanu Modi, the lead researcher of a groundbreaking trial that proved a drug that combines an antibody with a chemotherapy – trastuzumab deruxtecan (T-DXd) – can control cancer cells and extend survival in stage 4 HER2-low breast cancer patients.

Elacestrant is a new treatment option for patients with advanced breast cancer and ESR1 mutations in circulating tumor DNA. Oral selective estrogen receptor degraders are in multiple clinical trials with the potential to become a future mainstay of endocrine therapy.

The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only improved invasive-free survival in women with this type of early-stage breast cancer, but also improves distant disease-free survival and recurrence-free survival.

Two antibody-drug conjugates (ADCs) have been developed for HER2-negative and triple-negative breast cancer (TNBC): trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG); both ADCs outperformed current standard chemotherapy.